Q2 2015

Source filing unavailable

Q2 2015 · —

Revenue—

Net Income

-$2.59M

N/M vs Q2 2014

EPS Diluted

-$1.52

N/M vs Q2 2014

Operating Income-$2,596,000—

Operating Cash Flowderived-$2,862,000—

Free Cash Flowderived

Same quarter

Metric	Q2 2015	Q2 2014
Net Income	-$2.59M	-$2.23M
EPS Diluted	-$1.52	-$1.61

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR